rethinkTHC Search
Menu
Study breakdown

Over a third of Argentine MS patients use cannabis, but most never discuss it with their neurologist

Cross SectionalPreliminary evidence
The takeaway

Among 281 MS patients in Argentina, 34.2% were current cannabis users, but 54.3% had never discussed cannabis with their neurologist. Younger age, chronic pain, and alcohol use predicted cannabis use.

MS patients considering cannabis, neurologists treating MS, healthcare communication researchers

54.3% of cannabis-using MS patients never discussed it with their neurologist

What the researchers found

34.2% were current cannabis users, 22.7% former users. Among users, 31.3% used daily, 41.9% started after MS diagnosis, and 54.3% never discussed cannabis with their neurologist. Predictors of use were age under 30 (OR=2.39), chronic pain (OR=2.42), and current alcohol intake (OR=3.33).

Why it matters

The high prevalence of cannabis use among MS patients combined with low rates of physician discussion creates a dangerous information gap where patients may be making uninformed decisions about a substance that could interact with their MS treatments.

The numbers in context

281 patients; 34.2% current users; 22.7% former users; 31.3% daily use; 41.9% started post-diagnosis; 54.3% never discussed with neurologist; 47.5% recreational use

How the study worked

Cross-sectional online survey of 281 MS patients from Argentina, assessing demographics, quality of life, fatigue, anxiety/depression, sleep, disability, and cannabis use patterns.

What this study cannot tell us

Online survey with potential selection bias, self-reported cannabis use and disability, cross-sectional design, Argentina-specific context where cannabis legality is evolving.

How to read the evidence

Cross-sectional online survey from a single country with self-reported measures

When this study was published

Published in 2021 from Argentina, where medical cannabis regulations continue to evolve.

The bigger picture

This pattern of widespread cannabis use without physician involvement is seen across many chronic conditions and countries, suggesting a systemic failure in patient-provider communication about cannabis.

Questions still open

  • Why do most MS patients not discuss cannabis with their neurologist? Would provider-initiated conversations change use patterns? Are MS patients who use cannabis achieving better or worse disease outcomes?

Common questions

How common is cannabis use among MS patients?
In this Argentine survey, 34.2% of MS patients were current cannabis users and another 22.7% had used it previously. Nearly a third used it daily.
Do MS patients talk to their doctors about cannabis?
Most do not. Over 54% of cannabis-using MS patients in this study had never discussed their use with their neurologist, creating a significant gap in informed medical care.

Read the original research

Use of cannabis in patients with multiple sclerosis from Argentina.

Multiple sclerosis and related disorders, 51, 102932

Citation

Carnero Contentti, Edgar; López, Pablo A; Criniti, Juan; Pettinicchi, Juan Pablo; Tavolini, Dario; Mainella, Carolina; Tizio, Santiago; Tkachuk, Verónica; Silva, Berenice; Caride, Alejandro; Rojas, Juan I; Alonso, Ricardo. (2021). Use of cannabis in patients with multiple sclerosis from Argentina.. Multiple sclerosis and related disorders, 51, 102932. https://doi.org/10.1016/j.msard.2021.102932

Explore the wider topic